// App-Quantinova.ai

EP985 : REAL-WORLD DURATION OF TREATMENT (DOT) WITH LENALIDOMIDE-DEXAMETHASONE (RD)-BASED REGIMENS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): OUTCOMES FROM THE GLOBAL INSIGHT MM STUDY

Researchers

Presenter

  • Noemi Puig

Principal Investigators

  • Faith E. Davies

  • Ajai Chari

  • Jesus G. Berdeja

  • Mario Boccadoro

  • Roman Hjek

  • Robert M. Rifkin

  • Xavier Leleu

  • Evangelos Terpos

  • Caitlin L. Costello

  • Katja C. Weisel

  • Saad Z. Usmani

  • Frits van Rhee

  • Jeffrey A. Zonder

  • Michael A. Thompson

  • Jim Omel

  • Andrew Spencer

  • Vania T. M. Hungria

  • Gordon Cook

  • Jorge Vela-Ojeda

  • Mira Armour

  • Kaili Ren

  • Dasha Cherepanov

  • Dawn Marie Stull

  • Hans C. Lee

Medical Centers

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,United States

  • Clinica São Germano and Santa Casa Medical School,São Paulo,Brazil

  • Icahn School of Medicine at Mount Sinai, Jamaica, NY, United States

  • Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI

  • Levine Cancer Institute,Charlotte,United States

  • UMAE Especialidades Centro Medico La Raza IMSS,Ciudad de México,Mexico

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

  • Indiana University School of Medicine, Indianapolis, IN

  • Division of Hematology, University of Turin, Turin, Italy

  • Department of Haematooncology, University Hospital Ostrava and the Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

  • The Central Nebraska Myeloma Support Group, Grand Island, NE

  • Dept. of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Perlmutter Cancer Center at NYU Langone Health,New York,Stati Uniti

  • Mijelom CRO, Croatian Myeloma Support Association,Zagreb,Croatia

  • Pôle Régional de Cancérologie, Department of Hematology,CHU La Milétrie-Poitiers,Poitiers,Francia

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Tennessee Oncology and Sarah Cannon Research Institute,Nashville, TN,United States

  • Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia

  • Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Hematology Department,Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233),Salamanca,Spain

  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

Locations

  • United States

  • Brazil

  • Mexico

  • Italy

  • Czech Republic

  • Greece

  • Croatia

  • France

  • Australia

  • United Kingdom

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • III

Study Id's

  • NCT02761187

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved